

9. References

1. Fenichel R, Koerner J. Development of drugs that alter ventricular repolarization. <http://www.fenichel.net>, 1999.
2. Bednar, MM, Harrigan, EP, Anziano, RJ Camm AJ, Ruskin JN. The QT interval. Progress in Cardiovascular Diseases. 2001, 43:1-45.
3. Makkar, RR, Fromm BS, Steinman, RT, Meissner, MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. Journal of the American Medical Association. 1993, 270:2590-2597.
4. Malik M. Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol. 2001, 12(4):411-20.
5. Morganroth J, Brozovich FV, McDonald JT, Jacobs RA. Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol. 1991, 67(8):774-6.
6. Committee for Proprietary Medicinal Products. Points to consider: The Assessment of the Potential for QT interval prolongation by Non-cardiovascular medicinal products. The European Agency for the Evaluation of Medicinal Products. 17 December 1997.
7. Assessment of the QT prolongation potential of non-antiarrhythmic drugs. Health Canada. <http://www.hc-sc.gc.ca/hpb-dgps/therapeut/htmleng/guidmain.html>. March 15, 2001.
8. Safety pharmacology studies for assessing the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. February 7, 2002.
9. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Preliminary Concept Paper. FDA. November 15, 2002.
10. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss A, Shah R. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 2000;21(15):1216-31.
11. Shah RR. Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labeling of a new chemical entity. Fundamental & Clinical Pharmacology. 2002, 16:147-156.
12. Dmitrienko A, Smith BP. Analysis of the QT interval in clinical trials. Drug Information Journal 2002, 36:269-279.

13. Goldberg RJ, Bengtson J, Chen Z, et al: Duration of the QT interval and total and cardiovascular mortality in healthy persons (the Framingham Heart Study experience). *Am J Cardiol* 1991, 67:55-58.
14. Schouten EG, Dekker JM, Meppelink P, et al: QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. *Circulation* 1991, 84:1516-1523.
15. Elming H, Holm E, Jun L, et al: The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens. *Eur Heart J* 1998, 19:1391-1400.
16. de Bruyne MC, Hoes AW, Kors JA, et al: Prolonged QT interval predicts cardiac and all-cause mortality in the elderly. *Eur Heart J* 1999, 20:278-284.
17. Karjalainen J, Reunanen A, Ristola P, et al: QT interval as a cardiac risk factor in a middle aged population. *Heart* 1997, 77:543-548.
18. Dekker JM, Schouten EG, Klootwijk P, et al: Association between QT interval and coronary heart disease in middle-aged and elderly men: The Zutphen study. *Circulation* 1994, 90:779-785.
19. Padma-Nathan H, Eardley I, Kloner RA, Laties AM, Montorsi F. A 4-year update on the safety of sildenafil citrate (Viagra). *Urology* 2002, Vol 60(2 Suppl):67-90.
20. Shakir SA, Wilton LV, Boshier A, Layton D, Heeley E. Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England. *B.M.J.* 2001, 322:651-652.
21. Avelox® (moxifloxacin hydrochloride) tablets product information. Physicians Desk Reference. 2003, 57;870-75.
22. Noel GJ, Natarajan J, Chien S, Hunt T, Goodman DB, Abels RJ. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. *American Society for Clin Pharmacol Ther* 2003;73:292-303.
23. Bayer Corporation. Moxifloxacin studies submitted to FDA: MRR#1543, MRR#1544, MRR#1541, tablet IND #49,489 report serial #362. 2000;internal archive.
24. Malik M, Farbom P, Batchvarov V, Hnatkova K, Camm AJ. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. *Heart* 2002, 87;3:220-228.
25. Batchvarov VN, Ghuran A, Smetana P, Hnatkova K, Harries M, Dilaveris P, Camm AJ, Malik M. QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. *Am J Physiol Heart Circ Physiol*. 2002;282;6;H2356-63.

26. Geelen P, Drolet B, Rail J, Berube J, Daleau P, Rousseau G, Cardinal R, O'Hara GE, Turgeon J. Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. *Circulation*. 2000 Jul 18;102(3):275-7.